|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.365 HKD | -8.75% |
|
-14.12% | -20.65% |
| Mar. 26 | Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 10 | Livzon Pharma Recognizes Credit, Asset Impairments | MT |
Mabpharm Limited reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 44.02 million compared to CNY 28.85 million a year ago. Net loss was CNY 100 million compared to CNY 116.81 million a year ago.
Basic loss per share from continuing operations was CNY 0.02 compared to CNY 0.03 a year ago. Diluted loss per share from continuing operations was CNY 0.02 compared to CNY 0.03 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -20.65% | 211M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +2.13% | 22.25B | |
| -14.77% | 21.68B | |
| -8.79% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
MABPHARM LIMITED 
